Date: 2012-05-24
Type of information:
phase: 2
Announcement: initiation
Company: Kaketsuken (Japan)
Product: cell culture based pandemic flu vaccine co-developed with GlaxoSmithKline (GSK) and using Vivalis’ EB66® cell line
Action mechanism:
Disease: pandemic influenza
Therapeutic area: Infectious diseases
Country:
Trial details: Vivalis has announced that Kaketsuken has commenced a phase 2 clinical trial in Japan in April 2012, for the cell culture based pandemic flu vaccine being co-developed with GlaxoSmithKline (GSK) and using Vivalis’ EB66® cell line. In the “Program for preparing pandemic influenza vaccine development and production system”, the Japanese Ministry of Health, Labour and Welfare is taking the lead in establishing domestic production and supply of pandemic influenza vaccine using “cell-culture technology” . In order to contribute to the Program, Kaketsuken is aiming to early establish in Japan a domestic production and supply system for influenza vaccines co-developed with GSK, which vaccines are produced in Vivalis proprietary EB66® cell line in combination with GSK antigen-sparing adjuvant technology.
Latest news:
